In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
Access solutions: Reconciling potential for improved patient access with implementation realities
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...